cas 3240-94-6|| where to buy 4-(2-Chloroethyl)morpholine

製品名:4-(2-Chloroethyl)morpholine

IUPAC Name:4-(2-chloroethyl)morpholine

包装単位	有効在庫	価格（USD）
CM120000-10g	in stock	ƦƎ
CM120000-25g	in stock	ũƎǶ

研究開発用専用.

問い合わせフォーム

化学物質名

CAS番号

数量*

要求仕様*
（アッセイ %、材料グレード等）

お名前*

連絡先Eメールアドレス*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 3240-94-6 regularly via the above email.

追記事項

Verification code*

refresh

: CAS番号:3240-94-6; 分子式:C6H12ClNO; 融点:-; SMILESコード:ClCCN1CCOCC1; 密度:

: カタログ番号:CM120000; 分子量:149.62; 沸点:; MDL番号:MFCD00603731; 保管方法:

: Morpholines; Morpholine contains secondary amine groups and has all the typical reactive characteristics of secondary amine groups. It can react with inorganic acids to form salts, and react with organic acids to form salts or amides, which can be subjected to alkylation reaction, and can also be reacted with ethylene oxide, ketone or Willgerodt reaction. Morpholine is a six-membered ring containing oxygen and nitrogen, and its alkalinity is much lower than that of its parent piperidine. The marketed morpholine drugs are mainly distributed in the fields of tumors, cardiovascular and cerebrovascular diseases, respiratory system diseases, digestive system diseases, infectious diseases and mental disorders.; morpholine price; if you are interested in morpholine price, please feel free to contact us. More information of our products will be forwarded to you upon receipt of your specific inquiry.

: Tirbanibulin; Actinic keratosis (AK) is a chronic disease resulting from deleterious effects of long-term, cumulative, epidermal exposure to ultraviolet (UV) light.
Tirbanibulin is a synthetic, first-in-class, potent anti-proliferative agent that has shown antiproliferative and antitumoral effects in vitro and in vivo by inducing cell cycle arrest and ultimately apoptotic cell death. These effects have been attributed to the ability of tirbanibulin to reversibly bind to the colchicine-binding site on b-tubulin and inhibit tubulin microfilament polymerization.
The U.S. actinic keratosis treatment market size was valued at USD 2.94 billion in 2023 and is projected to reach USD 3.96 billion by 2033, growing at a CAGR of 3.04% from 2024 to 2033.